Recently, scholars have gradually paid attention to the relationship between ERBB2 and fibrosis, and they found that inhibition of HER2 can improve myocardial fibrosis caused by myocardial infarction or diabetes by regulating the TGF-β pathway (Amani et al., 2020; Humeres et al., 2021). Here, ERBB2 is linked to Myocardial fibrosis.